Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $127.40 USD
Change Today -0.40 / -0.31%
Volume 799.1K
VRTX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Mexico
Frankfurt
As of 8:10 PM 05/28/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Kenneth L. Horton

Special Counsel to the Chief Executive Officer, Vertex Pharmaceuticals Incorporated
AgeTotal Calculated CompensationThis person is connected to 6 board members in 1 different organizations across 3 different industries.

See Board Relationships
47$9,907,133
As of Fiscal Year 2014

Background*

Mr. Kenneth L. Horton, also known as Ken, has been Special Counsel to the Chief Executive Officer at Vertex Pharmaceuticals Incorporated since January 20, 2015. Mr. Horton served as the Chief Legal Officer and an Executive Vice President at Vertex Pharmaceuticals Incorporated from June 2012 to January 20, 2015. Mr. Horton was responsible for Vertex’s global legal and compliance functions. Mr. Horton served as General Counsel and an Executive Vice President of Corporate ...

Read Full Background

Corporate Headquarters*

50 Northern Avenue
Boston, Massachusetts 02210

United States

Phone: 617-341-6100
Fax: --

Board Members Memberships*

2007-Present
Director

Education*

BA
Dartmouth College
JD
Harvard Law School

Other Affiliations*

Annual Compensation*

Salary$465,000
Total Annual Compensation$465,000

Stock Options*

Restricted Stock Awards$5,741,425
All Other Compensation$3,253
Exercised Options64,321
Exercised Options Value$3,465,901
Exercisable Options42,640
Exercisable Options Value$2,221,369
Unexercisable Options174,664
Unexercisable Options Value$8,703,303
Total Value of Options$14,390,572
Total Number of Options281,625

Total Compensation*

Total Annual Cash Compensation$747,253
Total Short Term Compensation$465,000
Other Long Term Compensation$5,744,678
Total Calculated Compensation$9,907,133
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRTX:US $127.40 USD -0.40

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Richard F. Pops Chairman of the Board and Chief Executive Officer
Alkermes plc
$854.7K
Jean-Jacques Bienaime MBAChief Executive Officer and Director
BioMarin Pharmaceutical Inc.
$916.0K
Robert W. Duggan Chairman and Chief Executive Officer
Pharmacyclics Inc.
--
Herve Hoppenot Chief Executive Officer, President, Director and Member of Non-Management Stock Option Committee
Incyte Corporation
$2.9M
Bruce C. Cozadd Co-Founder, Executive Chairman and Chief Executive Officer
Jazz Pharmaceuticals Public Limited Company
$830.0K
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERTEX PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.